DK1032671T3 - Mammalt cytokin-lignende polypeptid-10 - Google Patents

Mammalt cytokin-lignende polypeptid-10

Info

Publication number
DK1032671T3
DK1032671T3 DK98960493T DK98960493T DK1032671T3 DK 1032671 T3 DK1032671 T3 DK 1032671T3 DK 98960493 T DK98960493 T DK 98960493T DK 98960493 T DK98960493 T DK 98960493T DK 1032671 T3 DK1032671 T3 DK 1032671T3
Authority
DK
Denmark
Prior art keywords
polypeptide
prevention
antibody
treatment
mammalian cytokine
Prior art date
Application number
DK98960493T
Other languages
Danish (da)
English (en)
Inventor
Angelika Grossmann
Darrell C Conklin
Betty A Haldeman
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1032671T3 publication Critical patent/DK1032671T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
DK98960493T 1997-11-26 1998-11-25 Mammalt cytokin-lignende polypeptid-10 DK1032671T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26

Publications (1)

Publication Number Publication Date
DK1032671T3 true DK1032671T3 (da) 2004-10-11

Family

ID=25526742

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98960493T DK1032671T3 (da) 1997-11-26 1998-11-25 Mammalt cytokin-lignende polypeptid-10

Country Status (20)

Country Link
EP (3) EP1719780A3 (uk)
JP (2) JP5191619B2 (uk)
KR (1) KR100574387B1 (uk)
CN (2) CN1618969A (uk)
AT (1) ATE269902T1 (uk)
AU (1) AU739420B2 (uk)
BR (1) BR9814904A (uk)
CA (1) CA2312000C (uk)
CZ (1) CZ300849B6 (uk)
DE (1) DE69824755T2 (uk)
DK (1) DK1032671T3 (uk)
EA (2) EA010741B1 (uk)
ES (1) ES2218872T3 (uk)
HU (1) HU227703B1 (uk)
IL (2) IL136076A0 (uk)
NO (2) NO326561B1 (uk)
NZ (1) NZ504751A (uk)
PL (2) PL195304B1 (uk)
UA (2) UA86350C2 (uk)
WO (1) WO1999027103A1 (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
JP4741139B2 (ja) 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60030769T2 (de) 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen
JP5015404B2 (ja) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド 可溶性ｚｃｙｔｏｒ１１サイトカイン受容体
EP1803733B1 (en) 2000-09-15 2010-03-10 ZymoGenetics, Inc. Polypeptides comprising the extracellular domains of IL-20RA and/or IL-20RB
AU2002220076A1 (en) * 2000-10-20 2002-05-06 Zymogenetics Inc. Secreted alpha-helical cytokine-like protein zlmda24
EP1390060A2 (en) * 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
WO2002070001A2 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
US20040204351A1 (en) * 2001-10-22 2004-10-14 Rowlinson Scott William Soluble proteins that inhibit cytokine signal transduction pathways
US7582287B2 (en) 2001-12-17 2009-09-01 Zymogenetics, Inc. Method for treating cervical cancer
BRPI0408705A (pt) * 2003-03-24 2006-03-07 Zymogenetics Inc método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
JP2007501813A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ 新生血管形成と関連した症状を治療および診断するためのインターロイキン−２０
WO2005052001A2 (en) 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
ATE506433T1 (de) 2003-12-19 2011-05-15 Novo Nordisk As Prozessierung von peptiden und proteinen
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2285979B2 (en) * 2008-05-27 2020-02-19 Dako Denmark A/S Hybridization compositions and methods
BRPI0914916A2 (pt) 2008-06-30 2015-10-20 Novo Nordisk As anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos
CA2739794A1 (en) * 2008-10-07 2010-04-15 National Cheng Kung University Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP2761028A1 (en) 2011-09-30 2014-08-06 Dako Denmark A/S Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
CN104245959B (zh) * 2012-03-05 2017-10-13 Seegene株式会社 基于探测和标记寡核苷酸切割及延伸试验的从靶核酸序列的核苷酸变异检测
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69637856D1 (en) * 1996-08-30 2009-04-16 Human Genome Sciences Inc Interleukin-19.
DE60030769T2 (de) * 1999-12-23 2007-10-25 Zymogenetics, Inc., Seattle Verfahren zur behandlung von entzündungen

Also Published As

Publication number Publication date
NO20002698L (no) 2000-07-20
HU227703B1 (en) 2011-12-28
EP1719780A3 (en) 2006-12-20
CA2312000C (en) 2013-03-26
AU1607799A (en) 1999-06-15
AU739420B2 (en) 2001-10-11
JP5331054B2 (ja) 2013-10-30
EA200000565A1 (ru) 2000-12-25
EA005581B1 (ru) 2005-04-28
NO20074516L (no) 2000-07-20
CZ20001910A3 (cs) 2000-11-15
HUP0100436A3 (en) 2003-08-28
UA86350C2 (en) 2009-04-27
IL136076A0 (en) 2001-05-20
JP2001524313A (ja) 2001-12-04
JP2010187698A (ja) 2010-09-02
EP1424393A3 (en) 2004-06-09
ATE269902T1 (de) 2004-07-15
ES2218872T3 (es) 2004-11-16
CN1618969A (zh) 2005-05-25
UA73275C2 (en) 2005-07-15
CN1247780C (zh) 2006-03-29
EP1719780A2 (en) 2006-11-08
NO326561B1 (no) 2009-01-12
NO20002698D0 (no) 2000-05-26
EP1424393A2 (en) 2004-06-02
CZ300849B6 (cs) 2009-08-26
KR100574387B1 (ko) 2006-04-27
BR9814904A (pt) 2000-10-03
HUP0100436A2 (hu) 2001-06-28
CA2312000A1 (en) 1999-06-03
PL195304B1 (pl) 2007-08-31
CN1282372A (zh) 2001-01-31
DE69824755T2 (de) 2005-08-04
NO329731B1 (no) 2010-12-13
KR20010032490A (ko) 2001-04-25
WO1999027103A1 (en) 1999-06-03
IL136076A (en) 2007-12-03
PL340755A1 (en) 2001-02-26
EP1032671B1 (en) 2004-06-23
PL198687B1 (pl) 2008-07-31
EP1032671A1 (en) 2000-09-06
EA010741B1 (ru) 2008-10-30
JP5191619B2 (ja) 2013-05-08
NZ504751A (en) 2001-10-26
DE69824755D1 (de) 2004-07-29
EA200401501A1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
NO20074516L (no) Pattedyrcytokinlignende polypeptid-1
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
IL210455A (en) A polypeptide for reducing mammalian signaling 13il, and using a polypeptide to produce a drug for up-regulating gene expression 2ra13-il in mammals
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
ATE534742T1 (de) Polypeptide und nukleinsäuren von phorphorymonas gingivalis
ATE140008T1 (de) Polypeptid
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE59710091D1 (de) Von Kaposi-sarkom assoziiertem Herpes-Virus (KSHV, HHV-8) kodiertes Polypeptid und dessen Verwendung in Diagnostik und Therapie
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
DE60325227D1 (uk)
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
EP0749981A4 (en) MONOCLONAL ANTIBODY
KR930019827A (ko) 신규 폴리펩티드 및 이를 암호하는 dna
MX9504057A (es) Proteina que tiene actividad tpo.
NZ606260A (en) Novel polypeptides involved in immune response
WO1999060117A3 (fr) Polypeptide prax-1